Get the Stockscreener App
8.24
2.36%
0.19
Champions Oncology Inc stock is traded at $8.24, with a volume of 4,252.
It is up +2.36% in the last 24 hours and up +29.76% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$8.05
Open:
$7.87
24h Volume:
4,252
Relative Volume:
0.11
Market Cap:
$89.32M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-11.61
EPS:
-0.71
Net Cash Flow:
$-4.86M
1W Performance:
+31.42%
1M Performance:
+29.76%
6M Performance:
+19.25%
1Y Performance:
+67.82%
1-Day Range:
$7.87
$8.24
1-Week Range:
$6.30
$8.5799
52-Week Range:
$3.6001
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
8.24 | 89.32M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.64 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.50 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.49 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.65 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.76 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Champions Oncology: Biological IP Is The Real AssetNot Preclinical Services - Seeking Alpha
Champions Oncology, Inc.'s (NASDAQ:CSBR) 11% gain last week benefited both private equity firms who own 30% as well as insiders - Yahoo Finance
After A Standout Q3, What's On The Horizon For Champions Oncology? - RTTNews
"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 1 - Yahoo
How To Trade (CSBR) - news.stocktradersdaily.com
Humanized Mouse and Rat Model Market worth US$409.8 million - openPR.com
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets™ - Barchart.com
(CSBR) Long Term Investment Analysis - news.stocktradersdaily.com
Positive Sentiment Still Eludes Champions Oncology, Inc. (NASDAQ:CSBR) Following 26% Share Price Slump - simplywall.st
Sixth Annual Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - Lehigh Valley Health Network
Heartland Oncology and Hematology Oncologist Named 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO) - Seeking Alpha
Leading Oncologist Wins ASCO's Top Advocacy Award for Fighting Cancer Care Barriers - Stock Titan
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - ACCESS Newswire
Where are the Opportunities in (CSBR) - news.stocktradersdaily.com
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies - marketscreener.com
CSBR Secures License for Radioactive Material Use in Preclinical Studies | CSBR Stock News - GuruFocus
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House - Bellingham Herald
Press Release Distribution & PR Platform - ACCESS Newswire
Champions Oncology Unlocks Next-Gen Cancer Treatment Capabilities with Strategic Radiotherapy License - Stock Titan
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.9 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.0 Million - ACCESS Newswire
Champions Oncology (CSBR) Partners with Turbine to Boost Drug Di - GuruFocus
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine - Stock Titan
Turbine Launches the World’s First Virtual Lab Using Cell Simulations - Business Wire
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets - The Malaysian Reserve
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year - Yahoo
I-Apollo Hospitals, yethula i-“Cancer Champions United” isinyathelo esiyingqayizivele sokunikeza amandla Abasinde Ngomdlavuza! - Apollo Hospitals
Patient Derived Xenograft Model Market Future Business - openPR.com
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 - ACCESS Newswire
Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding - simplywall.st
American Battery Technology boosts recycled battery output - Investing.com
Apollo Hospitals, yakhazikitsa "Cancer Champions United" njira yapadera yopatsa mphamvu Opulumuka Khansa! - Apollo Hospitals
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) - Yahoo Finance
Champions Oncology target raised to $12 at Craig-Hallum By Investing.com - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - MSN
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):